ERLOTIREL-150

About

This medication is a small molecule tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR). EGFR is a cell surface receptor that, when activated, plays a critical role in cell growth, proliferation, and survival. In many cancers, EGFR is overexpressed or harbors activating mutations, leading to uncontrolled signaling and tumor progression. By reversibly inhibiting the phosphorylation of EGFR, this medication effectively blocks the downstream signaling pathways, thereby inhibiting tumor cell proliferation, survival, and angiogenesis. It is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) in patients with specific EGFR activating mutations and, in combination with gemcitabine, for pancreatic cancer. Its targeted mechanism offers a personalized approach to cancer therapy, particularly for patients with specific genetic profiles.

Uses

• Non-small cell lung cancer (NSCLC) with EGFR mutations.
• Pancreatic cancer (in combination with gemcitabine).
• Other solid tumors with EGFR overexpression (investigational).
• Maintenance therapy for NSCLC.

Directions For Use

Take orally at least one hour before or two hours after a meal. Follow the prescribed dosage and schedule strictly.

Benefits

• Effective in NSCLC with specific EGFR mutations.
• Oral administration offers convenience.
• Targeted therapy with a distinct side effect profile.
• Improves progression-free survival.
• Can be used as first-line or maintenance therapy.
• Offers a personalized treatment option.

Side Effects

• Rash (acneiform)
• Diarrhea
• Anorexia
• Fatigue
• Nausea
• Vomiting
• Stomatitis (mouth sores)
• Dry skin
• Conjunctivitis
• Interstitial lung disease (rare, serious)
• Gastrointestinal perforation (rare)
• Hepatotoxicity (rare)

Safety Measures

• Alcohol - Avoid or limit alcohol, as it may exacerbate gastrointestinal side effects and potentially increase liver strain.
• Pregnancy - Contraindicated due to potential for fetal harm; effective contraception is required during treatment.
• Breastfeeding - Not recommended; discontinue breastfeeding due to potential for serious adverse reactions in the infant.
• Liver - Use with caution; dose adjustments may be necessary in patients with hepatic impairment.
• Kidney - Use with caution; no specific dose adjustment required for mild to moderate renal impairment, but monitor closely.
• Lung - Monitor closely for new or worsening pulmonary symptoms (e.g., dyspnea, cough, fever); interstitial lung disease is a rare but serious side effect.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.